Please share experience of venetoclax plus obi... - CLL Support

CLL Support

22,513 members38,668 posts

Please share experience of venetoclax plus obinutuzimab or acalabrutinib treatment in a survey that may help others gain access?

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin
2 Replies

Dear UK and international friends please can you help us as we press for access to new CLL treatments.

UK patient groups & charities work together with groups in other countries to strengthen our UK access submissions during NICE appraisal of new drugs.

WE NEED YOUR HELP

You may have seen and responded to this request for help in this survey lead by Canadian CLL groups, it was posted a while back by CLLPAG healthunlocked.com/cllsuppo...

IF YOU ARE IN THE UK OR IN COUNTRIES OUTSIDE OF CANADA AND HAVE BEEN TREATED WITH OR ARE IN TREATMENT WITH ONE OF THE TREATMENTS BELOW YOU CAN HELP BY COMPLETING THIS SURVEY:

surveymonkey.com/r/CLLCAN2020

1.Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

2.Acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

3.Acalabrutinib (Calquence) monotherapy for treatment of relapsed/refractory CLL/SLL

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE NEW TREATMENTS IN CANADA AND YOUR OWN COUNTRY.

The survey will be open until midnight Pacific Time on Friday, February 28th, 2020 and should only take 10 minutes of your time.

You can access the survey here: surveymonkey.com/r/CLLCAN2020

Thank you

Nick

Written by
HAIRBEAR_UK profile image
HAIRBEAR_UK
Founder Admin
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Jm954 profile image
Jm954Administrator

This is a very important survey, the results of which will help to inform our responses to new treatment consultation documents and influence treatment throughout the world.

Patient experiences are vitally important and very important as part of this assessment process.

PLEASE, if you have received the following treatments, complete the survey - thank you.

- Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

- Acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

- Acalabrutinib (Calquence) monotherapy for treatment of relapsed/refractory CLL/SLL

Many thanks, it's appreciated.

Jackie

UK-Sparky profile image
UK-Sparky

Have completed quite short and easy.

You may also like...

Please share experience of venetoclax plus obinutuzimab or acalabrutinib mono treatment in an important survey

Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL Acalabrutinib...

Survey for CLL patients having taken Venetoclax or Acalabrutinib

CLL/SLL Patient Survey If you have CLL or SLL and have been treated with the following therapies,...

Please Help with the Global Leukaemia Patient Experience Survey 2021

needs of leukaemia patients. The survey collects key data on important areas of patient experience...

UK NICE Approves Ibrutinib +Venetoclax for First Line treatment for ALL Patients from today

ALL CLL patients as their first treatment if their doctor feels it is appropriate. This treatment...

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

higher in the venetoclax group (85% vs. 71%). The PFS benefit was observed in the venetoclax group,...